TOBAM’s Amedisys AMED Stock Holding History

TOBAM’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-131	Closed	-$32K	–	431
2021 Q2	$32K	Hold	131	–	–	﹤0.01%	417
2021 Q1	$35K	Hold	131	–	–	﹤0.01%	403
2020 Q4	$38K	Hold	131	–	–	﹤0.01%	374
2020 Q3	$31K	Buy	+131	New	+$29.8K	﹤0.01%	368

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

TOBAM's AMED Position: Q3 2021 in Review

TOBAM sold out of Amedisys (AMED) in Q3 2021, closing a stake of 131 shares — an estimated $32K sold.

TOBAM first reported a position in AMED in Q3 2020 and held it in 4 quarters. The position peaked at $38K in Q4 2020. 351 funds tracked by Wall St. Rank hold AMED as of Q3 2021.

TOBAM reported no remaining Amedisys position as of Q3 2021 after selling out during the quarter.
TOBAM sold 131 Amedisys shares in Q3 2021, an estimated $32K.
TOBAM first reported a position in Amedisys in Q3 2020 and held it in 4 quarters.
TOBAM's Amedisys position peaked at $38K in Q4 2020.
351 funds tracked by Wall St. Rank held Amedisys as of Q3 2021.

Based on TOBAM's 13F filing for Q3 2021, filed 12 Nov 2021.